Monogram Biosciences, Inc. (formerly ViroLogic Inc.) is an international biotechnology laboratory located in South San Francisco, California, USA and is a subsidiary of LabCorp. Monogram develops and markets assays to help guide and improve the treatment of infectious diseases (including HIV and Hepatitis) and cancer.

Virologic was founded in 1996 by Daniel Capon, Ph.D., Martin Goldstein and Robert S. Capon. The company went public (NASDAQ: VLGC) in 2000.

Monogram was acquired by Laboratory Corporation of America in June 2009.

References

External links

• Baseline HIV Type 1 Coreceptor Tropism Predicts Disease Progression http://www.journals.uchicago.edu/doi/abs/10.1086/520650

• Four Studies Affirm Significance Of Monogram's Trofile(TM) HIV Co-Receptor Tropism Assay http://www.medicalnewstoday.com/articles/49493.php

• Accuracy of Monogram's Trofile Assay in Determining Tropism and New Tropism Assays in Development http://www.natap.org/2007/DrugResistance/DrugRes_13.htm

• Trofile Bests SensiTrop as Most Reliable Tropism Test http://www.poz.com/articles/hiv_tropism_trofile_sensitrop_761_13714.shtml?rss=true

• Monogram Biosciences teams up with Pfizer for HIV treatment http://www.wallst.net/editorials/article.asp?id=785

• Monogram Biosciences Launches New "Trofile" HIV Co-receptor Tropism Test to Select Patients Eligible to User CCR5 Antagonist Maraviroc (Selzentry) http://www.hivandhepatitis.com/recent/2007/081407_a.html